Evidence map›Paper›PMID 40076117›Full record

ArticlePolymers2025

High-Density Lipoprotein Biomimetic Inorganic-Organic Composite Nanosystem for Atherosclerosis Therapy.

Yunpeng Zhang, Danni Liu, Yaoqi Wang, Qi Sun, Dong Mei, Xiaoling Wang, Yan Su, Siyu Liu, Chunying Cui, Shuang Zhang

Abstract read
In one paragraph

Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yunpeng ZhangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Danni LiuSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Yaoqi WangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Qi SunSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0009-0005-9117-9134
Dong MeiLaboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.
Xiaoling WangLaboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.
Yan SuLaboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China.
Siyu LiuSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Chunying CuiSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Shuang ZhangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-1441-9884

Funding

2023KJ000814 2020KJ000514Cooperation Research Funding of Capital Medical University 2023KJ000814National Natural Science Foundation of China 81502688National Natural Science Foundation of China 82404529R&D Program of Beijing Municipal Education Commission KM202210025024
6 · The paper itself

Abstract

Atherosclerosis (AS) is an important causative agent of cardiovascular diseases, and the occurrence and development of AS is accompanied by oxidative stress, so antioxidant therapy has become one of the strategies for the treatment of AS. This study aimed to design and construct an apolipoprotein ApoA1-modified inorganic-organic composite nanosystem for AS therapy, in which ApoA1 was modified onto carboxylated CeO

Indexed as

antioxidantApoA1atherosclerosiscerium-manganese hybridized nanoparticles

Identifiers

PMID40076117
PMCPMC11902788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.